12:00 AM
May 10, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SU5416: Began Phase I/II studies

Sugen Inc. (SUGN), South San Francisco, Calif.
Product: SU5416
Business: Cancer
Therapeutic category: Angiogenesis
Target: Flk-1/KDR receptor
Description: Small molecule inhibitor of...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >